Key Findings
Investment in in vivo cell therapies, where therapeutic cells like CAR T cells are generated directly within the patient’s body, is rapidly expanding across the biopharmaceutical industry. This approach holds the potential to significantly reduce the treatment burden, complex ex vivo manufacturing, and high costs associated with conventional cell therapies, prompting major pharmaceutical companies like Eli Lilly and Company to strategically enter this field.
Technical / Clinical Details
In vivo cell therapy utilizes gene editing technologies (e.g., lentiviral vectors or circular RNA) to ‘reprogram’ existing cells within the patient’s body (e.g., T cells) into therapeutic cells like CAR T cells. This eliminates the need for complex and time-consuming processes such as cell collection, ex vivo manipulation, and re-infusion. Eli Lilly and Company’s recent acquisitions underscore its commitment to this technology.
- Acquisition of Kelonia Therapeutics: Kelonia Therapeutics’ ‘iGPS lentiviral gene delivery system’ enables efficient in vivo genetic modification of cells. This allows for the targeted delivery of therapeutic genes to specific tissues or cell types, generating therapeutic cells that exert their effects directly within the patient’s body.
- Acquisition of Orna Therapeutics: Orna Therapeutics’ circular RNA (circRNA)-based in vivo CAR-T therapy enables stable and efficient gene expression, facilitating the in vivo generation of CAR T cells. Circular RNAs are more resistant to degradation than linear RNAs, promising more sustained protein expression.
These technologies aim to simplify cell therapy logistics and dramatically reduce manufacturing costs, thereby expanding access to more patients.
Background & Context
While traditional autologous CAR T cell therapy has achieved breakthrough efficacy in certain blood cancers, its manufacturing requires several weeks, high costs, and specialized facilities. Consequently, many patients face prolonged waits for treatment, and in some cases, are unable to receive the therapy at all. In vivo cell therapy is emerging as a next-generation solution to overcome these bottlenecks, potentially making CAR T cell therapy available to a broader patient population. The active investment in this field by major pharmaceutical companies like Eli Lilly indicates that the in vivo approach is a leading trend shaping the future of cell and gene therapy.
Strategic Significance & Outlook
The surging investment in in vivo cell therapy is expected to bring about a significant transformation in the cell therapy commercialization model. If reduced treatment burden and cost savings are realized, advanced cell therapies, including CAR T cell therapies, could be adapted for a wider range of diseases and become more accessible to patients worldwide. The integration of Kelonia’s and Orna’s technologies will strengthen Eli Lilly’s cell and gene therapy pipeline, playing a crucial role in establishing its leadership in this innovative sector. Investors are keenly interested in the clinical trial results of in vivo approaches and their impact on the growth and sustainability of the cell therapy market.
Source: https://www.dcatvci.org/features/in-vivo-cell-therapies-solving-mfg-obstacles/
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments